# A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

> **NCT03393013** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kezar Life Sciences, Inc.** · enrollment: 69 (actual)

## Conditions studied

- Lupus Nephritis
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** KZR-616

## Key facts

- **NCT ID:** NCT03393013
- **Lead sponsor:** Kezar Life Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-20
- **Primary completion:** 2022-08-04
- **Final completion:** 2022-08-04
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393013, "A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03393013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*